Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): A stressor on the immune system

Immunology

Volumn 111, Issue 4, 2004, Pages 357-367

  Connor, Thomas J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOLAMINE; CD4 ANTIGEN; CYTOKINE; DOPAMINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

BEHAVIOR; CYTOKINE PRODUCTION; DRUG ABUSE; HUMAN; HYPERTHERMIA; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INHIBITION KINETICS; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STIMULATION; STRESS; T LYMPHOCYTE; TH2 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; HALLUCINOGENS; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SUBSTANCE-RELATED DISORDERS;

EID: 1842784951     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0019-2805.2004.01847.x     Document Type: Review

References (88)

1. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16:209-19.
2. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol 1998; 83:102-15.
3. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J Neuroimmunol 1998; 83:19-28.
4. Nunez-Iglesias MJ, Castro-Bolano C, Losada C et al. Effects of amphetamine on cell-mediated immune response in mice. Life Sci 1996; 58:L29-33.
5. Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol 1998; 83:139-47.
6. Yu Q, Zhang D, Walston M, Zhang J, Liu Y, Watson RR. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int Immunopharmacol 2002; 2:951-62.
7. Alonzo NC, Bayer BM. Antagonism of N-methyl-D-aspartate receptors reduces the vulnerability of the immune system to stress after chronic morphine. J Pharmacol Exp Ther 2003; 307:793-800.
8. Avila AH, Alonzo NC, Bayer BM. Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine. J Neuroimmunol 2004; 147:109-13.
9. Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998; 83:116-23.
10. Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 2002; 8:240-9.
11. Nunez MJ, Fernandez-Rial JC, Coucciro J, Suarez JA, Gomez-Fernandez DE, Rey-Mendez M, Freire-Garabal M. Effects of amphetamine on influenza virus infection in mice. Life Sci 1993; 52:PL73-78.
12. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol 1998; 83:4-18.
13. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 1998; 83:133-8.
14. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83:77-87.
15. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55:463-508.
16. Hegadoren KM, Baker GB, Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 1999; 23:539-53.
17. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 1998; 59:1003-9.
18. Koch S, Galloway MP. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 1997; 104:135-46.
19. Callaway CW, Wing LL, Geyer MA. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990; 254:456-64.
20. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003; 27:199-217.
21. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001; 16:589-98.
22. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 2002; 135:170-80.
23. Nash JF Jr, Meltzer HY, Gudelsky GA. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4 methylenedioxymethamphetamine. J Pharmacol Exp Ther 1988; 245:873-9.
24. Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine on monoaminergic systems in rat brain. Eur J Pharmacol 1986; 128:41-8.
25. Stone DM, Merchant KM, Hanson GR, Gibb JW. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in the brain of rat. Neuropharmacology 1987; 26:1677-83.
26. Harkin A, Shanahan E, Kelly JP, Connor TJ. Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. Eur J Neurosci 2003; 18:1021-7.
27. Connor TJ, O'Shaughnessy D, Kelly JP. Methylenedioxymethamphetamine ('MDMA; Ecstasy') suppresses zymozan-induced oxidative burst in neutrophils. Ir J Med Sci 2004; (in press).
28. Connor TJ, Harkin A, Kelly JP. Methylenedioxymethamphetamine (MDMA; 'Ecstasy') increases LPS-induced IL-10 production via β-adrenoceptor activation. Eur Cytokine Netw 2003; 14 (Suppl.):47.
29. 2a and IFN-γ production. Immunol Lett 2001; 78:67-73.
30. Connor TJ, Dennedy MC, Harkin A, Kelly JP. Methylenedioxymethamphetamine- induced suppression of interleukin-1β and tumour necrosis factor-α is not mediated by serotonin. Eur J Pharmacol 2001; 418:147-52.
31. Connor TJ, Kelly JP, McGee M, Leonard BE. Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1β and TNF-α secretion following an in vivo lipopolysaccharide challenge. Life Sci 2000; 67:1601-12.
32. Connor TJ, Kelly JP, Leonard BE. An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats. Immunopharmacology 2000; 46:223-35.
33. Connor TJ, McNamara MG, Kelly JP, Leonard BE. 3,4- methlyenedioxymethamphetamine (MDMA; Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat. Human Psychopharmacol 1999; 14:95-104.
34. Connor TJ, McNamara MG, Finn D, Currid A, O'Malley M, Redmond AM, Kelly JP, Leonard BE. Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology 1998; 38:253-60.
35. Pacifici R, Pichini S, Zuccaro P et al. Paroxetine inhibits acute effects of MDMA on the immune system in humans. J Pharmacol Exp Ther 2004; (in press).
36. Pacifici R, Zuccaro P, Farre M et al. Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus non-controlled settings. Ann N Y Acad Sci 2002; 965:421-33.
37. Pacifici R, Zuccaro P, Farre M et al. Effects of repeated doses of MDMA ('ecstasy') on cell-mediated immune response in humans. Life Sci 2001; 69:2931-41.
38. Pacifici R, Zuccaro P, Hernandez Lopez C et al. Acute effects of 3,4 methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 2001; 296:207-15.
39. Pacifici R, Zuccaro P, Farre M et al. Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 1999; 65:PL309-16.
40. Beutler B. Tumor necrosis factor, immunity and inflammatory disease: lessons of the past decade. J Invest Med 1995; 43:227-35.
41. Kalinski P, Storkus WJ, Thompson AW, Lotze MT. Interleukin-12 family [IL-12, 23, 12RA, 27]. In: Thompson AW, Lotze MT, eds. The Cytokine Handbook, 4th edn. San Diego: Academic Press, 2003:383-408.
42. Henderson B. Interleukin-1. In: Dale MM, Foreman JC, Fan TD, eds. Textbook of Immunopharmacology, 3rd edn. Oxford: Blackwell Scientific Publications, 1988:193-9.
43. Tracey KJ. Tumor necrosis factor-α. In: Thompson A, ed. The Cytokine Handbook, 2nd edn. London: Academic Press, 1994: 289-304.
44. Bogdan C, Paik J, Vodovotz Y, Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem 1992; 267:23301-8.
45. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
46. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage co-stimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151:1224-34.
47. Gerard C, Bruyns C, Marchant A et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-50.
48. Gordon J, Barnes NM. Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol 2003; 24:438-43.
49. Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998; 12:249-71.
50. House RV, Thomas PT, Bhargava HN. Selective modulation of immune function resulting from in vitro exposure to methylenedioxymethamphetamine (Ecstasy). Toxicology 1995; 96:59-69.
51. Dantzer R, Kelley KW. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci 1989; 44:1995-2008.
52. Serafeim A, Gordon J. The immune system gets nervous. Curr Opin Pharmacol 2001; 1:398-403.
53. Grob SC, Russell EP, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 1996; 73:103-7.
54. Connor TJ, Kelly JP. Fenfluramine-induced immunosuppression: an in vivo analysis. Eur J Pharmacol 2002; 455:175-85.
55. Dennedy MC, Connor TJ, Harkin A, Kelly JP, O'Donnell JM. Does serotonin mediate the immunosuppressive effects of methylenedioxymethamphetamine and fenfluramine in rats? Ir J Med Sci 2000; 169:360.
56. Connor TJ, O'Mahony S, Kelly JP, Harkin A. Augmentation of serotonergic function suppresses pro-inflammatory cytokine production in response to an in vivo immune challenge. Ir J Med Sci 2003; 172 (Suppl. 2):23.
57. Freire-Garabal M, Balboa JL, Nunez MJ, Castano MT, Llovo JB, Fernandez-Rial JC, Belmonte A. Effects of amphetamine on T-cell immune response in mice. Life Sci 1991; 49: PL107-112.
58. Pezzone MA, Rush KA, Kusnecov AW, Wood PG, Rabin BS. Corticosterone- independent alteration of lymphocyte mitogenic function by amphetamine. Brain Behav Immun 1992; 6:293-9.
59. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 1999; 64:29-34.
60. Cryan JF, Harkin A, Naughton M, Kelly JP, Leonard BE. Characterization of D-fenfluramine-induced hypothermia, evidence for multiple sites of action. Eur J Pharmacol 2000; 390:275-85.
61. Bateman A, Singh A, Kral T, Solomon S. The immune-hypothalamic-pituitary- adrenal axis. Endocr Rev 1989; 10:92-112.
62. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52:595-638.
63. Kut JL, Young MR, Crayton JW, Wright MA, Young ME. Regulation of murine T-lymphocyte function by spleen cell-derived and exogenous serotonin. Immunopharmacol Immunotoxicol 1992; 14:783-96.
64. Stefulj J, Cicin-Sain L, Schauenstein K, Jernej B. Serotonin and immune response: effect of the amine on in vitro proliferation of rat lymphocytes. Neuroimmunomodulation 2001; 9:103-8.
65. Eugen-Olsen J, Afzelius P, Andresen L, Iversen J, Kronborg G, Aabech P, Nielsen JO, Hofmann B. Serotonin modulates immune function in T cells from HIV-seropositive subjects. Clin Immunol Immunopathol 1997; 84:115-21.
66. Nash JF, Arora RC, Schreiber MA, Meltzer HY. Effect of 3,4 methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats. Biochem Pharmacol 1991; 41:79-84.
67. Stuerenburg HJ, Petersen K, Baumer T, Rosenkranz M, Buhmann C, Thomasius R. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuroendocrinol Lett 2002; 23:259-61.
68. Hasko G, Szabo C, Nemeth ZH, Deitch EA. Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a β-adrenoceptor-mediated mechanism. J Neuroimmunol 2002; 122:34-9.
69. Carr L, Tucker A, Fernandez-Botran R. In vivo administration of L-dopa or dopamine decreases the number of splenic IFN gamma-producing cells. J Neuroimmunol 2003; 137:87-93.
70. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, Bhattacharya D, Dasgupta PS. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol 2003; 3:1019-26.
71. + T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 2001; 9:23-33.
72. Connor TJ, Brewer C, Harkin A, Kelly JP. Acute stress promotes an immunosuppressive cytokine phenotype: a role for catecholamines. Brain Behav Immun 2003; 17:168.
73. Meltzer JC, MacNeil BJ, Sanders V, Pylypas S, Jansen AH, Greenberg AH, Nance DM. Stress-induced suppression of in vivo splenic cytokine production in the rat by neural and hormonal mechanisms. Brain Behav Immun (in press).
74. Engler H, Stefanski V. Social stress and T cell maturation in male rats: transient and persistent alterations in thymic function. Psychoneuroendocrinology 2003; 28:951-69.
75. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8:223-46.
76. Matalka KZ. Neuroendocrine and cytokines-induced responses to minutes, hours, and days of mental stress. Neuroendocrinol Lett 2003; 24:283-92.
77. Elenkov IJ. Systemic stress-induced Th2 shift and its clinical implications. Int Rev Neurobiol 2002; 52:163-86.
78. Connor TJ, Kelly JP, Leonard BE. Forced swim test-induced neurochemical endocrine, and immune changes in the rat. Pharmacol Biochem Behav 1997; 58:961-7.
79. Bachen EA, Manuck SB, Marsland AL, Cohen S, Malkoff SB, Muldoon MF, Rabin BS. Lymphocyte subset and cellular immune responses to a brief experimental stressor. Psychosom Med 1992; 54:673-9.
80. Gerra G, Monti D, Panerai AE et al. Long-term immune-endocrine effects of bereavement: relationships with anxiety levels and mood. Psychiatry Res 2003; 121:145-58.
81. Benschop RJ, Jacobs R, Sommer B, Schurmeyer TH, Raab JR, Schmidt RE, Schedlowski M. Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. FASEB J 1996; 10:517-24.
82. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in tumor necrosis factor alpha-deficient mice: a critical requirement for tumor necrosis factor alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184:1397-411.
83. Denis M, Ghadirian E. Interleukin-1 is involved in mouse resistance to Mycobacterium avium. Infect Immun 1994; 62:457-61.
84. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24:603-9.
85. Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. Int J Hematol 2003; 78:7-17.
86. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002; 17:309-12.
87. Prasad N, Cargill R, Wheeldon NM, Long CC, McDonald TM. 'Ecstasy' and meningococcal meningitis. Infect Dis Clin Pract 1994; 3:122-3.
88. Klitzman RL, Pope HG Jr, Hudson JI. MDMA ('Ecstasy') abuse and high-risk sexual behaviors among 169 gay and bisexual men. Am J Psychiatry 2000; 157:1162-4.